Angion Biomedica Corp

-0.11 (-6.04%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)51.23M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$1.01 Million
Adjusted EPS-$0.51
See more estimates
10-Day MA$1.75
50-Day MA$1.51
200-Day MA$3.43
See more pivots

Angion Biomedica Corp Stock, NASDAQ:ANGN

51 Charles Lindbergh Boulevard, Suite 1200, Uniondale, New York 11553
United States of America
Phone: +1.415.655.4899
Number of Employees: 71


Angion Biomedica Corp. operates as a biopharmaceutical company. The firm focuses on the discovery and development of novel therapeutic agents to address acute organ injuries and fibrotic diseases. Its product pipeline includes ANG-3777, ANG-3070, ROCK2 Inhibitor and CYP11B2 Inhibitors. The company was founded by Itzhak D. Goldberg on April 06, 1998 and is headquartered in Uniondale, NY.